Show simple item record

dc.contributor.authorMtewa, Andrew G.
dc.contributor.authorAmanjot, Annu
dc.contributor.authorLampiao, Fanuel
dc.contributor.authorOkella, Hedmon
dc.contributor.authorWeisheit, Anke
dc.contributor.authorTolo, Casim U.
dc.contributor.authorOgwang, Patrick
dc.date.accessioned2023-01-20T07:09:23Z
dc.date.available2023-01-20T07:09:23Z
dc.date.issued2022
dc.identifier.citationMtewa, Andrew G.et.al. (2022), SARS-CoV-2 vaccine development,;Coronavirus Drug Discoveryen_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/2720
dc.description.abstractVaccine development is the entire process involved in the designing of a vaccine to the post release study period. Vaccines work against viruses, bacteria, fungi and parasites. The design in which an antiviral vaccine is made is in such a way that it boosts the natural human immune response to an incoming virus by priming. In this way, the immune system is able to recognize antigens particular to the virus or for better vaccines, a particular strain of the virus [1]. The antigens have characteristic molecules that are found on the surface of the virus making it easily identifiable within a very short period. The response is that the immune system is ideally releasing immune cells that attack the viruses directly or by the release of antibodies Coronavirus. upon being triggered by the mere presence of the antigens. The antibodies get themselves attached to the virus and then immune cells engulf and destroy it.en_US
dc.language.isoen_USen_US
dc.publisherCoronavirus Drug Discoveryen_US
dc.subjectVaccinesen_US
dc.subjectCOVID-19en_US
dc.subjectDrugsen_US
dc.titleSARS-CoV-2 vaccine developmenten_US
dc.typeBook chapteren_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record